Hrt Financial LP Akebia Therapeutics, Inc. Transaction History

Hrt Financial LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$0.8 - $1.28 $12,075 - $19,320	15,094 New	15,094 $18,000
Q1 2023 May 12, 2023	BUY	$0.56 - $1.15 $83,261 - $170,983	148,681 New	148,681 $83,000
Q3 2022 Nov 14, 2022	SELL	$0.3 - $0.46 $324,085 - $496,930	-1,080,284 Reduced 97.88%	23,453 $7,000
Q2 2022 Aug 12, 2022	BUY	$0.32 - $0.67 $345,110 - $722,574	1,078,469 Added 4268.12%	1,103,737 $389,000
Q1 2022 May 16, 2022	SELL	$0.72 - $2.93 $254,376 - $1.04 Million	-353,300 Reduced 93.33%	25,268 $18,000
Q4 2021 Feb 14, 2022	BUY	$2.26 - $3.34 $855,563 - $1.26 Million	378,568 New	378,568 $855,000
Q3 2021 Nov 15, 2021	SELL	$2.35 - $3.88 $146,748 - $242,290	-62,446 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$2.83 - $4.2 $570,344 - $846,447	-201,535 Reduced 76.34%	62,446 $236,000
Q1 2021 May 17, 2021	BUY	$2.92 - $5.06 $770,824 - $1.34 Million	263,981 New	263,981 $893,000
Q4 2019 Feb 14, 2020	SELL	$3.16 - $6.73 $51,719 - $110,149	-16,367 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$3.55 - $5.4 $58,102 - $88,381	16,367 New	16,367 $64,000

120

54.9M

291K

179K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $417M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.